Sigma Healthcare Limited (ASX: SIG) delivered a strong first full-year performance following its transformational combination with Chemist Warehouse Group, with FY26 results announced on 27 August 2026. Revenue and earnings advanced at double-digit rates, while stronger margins, international expansion and early merger synergies showed the enlarged pharmacy group is beginning to convert greater scale into operating leverage.Highlights:

• Earnings outpaced sales growth, signalling stronger benefits from Sigma’s enlarged operating platform.
• International EBIT surged 91.3%, opening another potential engine beyond Australia.
• Early synergies reached AU$32.6 million, but the bigger FY29 target remains ahead.

Earnings Momentum BuildsFY26 revenue climbed 15.5% to AU$10.8 billion, while normalised EBIT advanced 20.6% to AU$1.09 billion. Normalised NPAT increased 22.3% to AU$732.3 million, demonstrating that earnings expanded faster than the top line. The normalised EBIT margin improved to 10.1%, supported by scale efficiencies and disciplined cost management.

Australia remained Sigma’s dominant earnings contributor, generating AU$10.41 billion in revenue and AU$1.03 billion in normalised EBIT, up 14.9% and 18.3%, respectively. Chemist Warehouse branded network sales reached about AU$10.2 billion, supported by 13.4% like-for-like growth and 24 new Australian stores.International Growth AcceleratesOffshore operations delivered a sharper earnings uplift. International revenue rose 33.0% to AU$421.4 million, while normalised EBIT jumped 91.3% to AU$55.8 million. Ireland became profitable for the first time, while New Zealand remained a key growth market. Sigma expects two UK stores to open before the end of calendar 2026, extending its international footprint.

Balance-sheet leverage also improved, with net debt falling to AU$663.2 million from AU$752.2 million and net debt-to-normalised EBITDA declining to 0.57 times.Outlook: Execution Takes Centre StageSigma enters FY27 with substantial expansion plans. During 1H27, the company expects to onboard 13 Australian Chemist Warehouse stores and 19 international stores, alongside 42 Amcal and Discount Drug Stores openings.

The integration program remains another major earnings lever. Sigma delivered AU$32.6 million of synergies in FY26 and remains on track for AU$100 million annually by FY29. The central question for investors is now whether Sigma can sustain its sales momentum while converting international expansion, network growth and remaining merger efficiencies into durable earnings and cash-flow growth.Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au